Targeting mutant p53 in human tumors

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3648-3650

  Lehmann, Brian D ^a   Pietenpol, Jennifer A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; APR 246; DNA BINDING PROTEIN; NUTLIN; PRIMA 1; PROTEIN BAX; PROTEIN MDM2; PROTEIN MDMX; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; SERDEMETAN; SYNTHETIC PEPTIDE; THIOSEMICARBAZONE DERIVATIVE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CELL CYCLE ARREST; CELL STRESS; DNA REPAIR; DNA SEQUENCE; GAIN OF FUNCTION MUTATION; GENE ACTIVITY; GENE FREQUENCY; GENE MUTATION; HUMAN; LUNG CANCER; NEOPLASM; NONHUMAN; OLIGOMERIZATION; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SENESCENCE; TUMOR GROWTH; WILD TYPE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PATIENT SAFETY; QUINUCLIDINES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867598079     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.0412     Document Type: Review

References (29)

1. Goh AM, Coffill CR, Lane DP: The role of mutant p53 in human cancer. J Pathol 223:116-126, 2011
2. Lehmann S, Bykov VJN, Ali D, et al: Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30:3633-3639, 2012
3. Xu J, Reumers J, Couceiro JR, et al: Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7:285-295, 2011
4. Brosh R, Rotter V: When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer 9:701-713, 2009
5. Do PM, Varanasi L, Fan S, et al: Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 26:830-845, 2012
6. Soussi T: p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cancer cell 3:303-305, 2003
7. Coffill CR, Muller PA, Oh HK, et al: Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep 13:638-644, 2012
8. Momand J, Zambetti GP, Olson DC, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
9. Riemenschneider MJ, Büschges R, Wolter M, et al: Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59:6091-6096, 1999 (Pubitemid 30035626)
10. Esteller M, Tortola S, Toyota M, et al: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60:129-133, 2000 (Pubitemid 30058742)
11. Vassilev LT, Vu BT, Graves B, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848, 2004 (Pubitemid 38174664)
12. Kim AL, Raffo AJ, Brandt-Rauf PW, et al: Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 274:34924-34931, 1999 (Pubitemid 129509540)
13. Kojima K, Burks JK, Arts J, et al: The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 9:2545-2557, 2010
14. Issaeva N, Bozko P, Enge M, et al: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321-1328, 2004 (Pubitemid 40022713)
15. Shangary S, Qin D, McEachern D, et al: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A 105:3933-3938, 2008 (Pubitemid 351723502)
16. Popowicz GM, Czarna A, Wolf S, et al: Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9:1104-1111, 2010
17. Reed D, Shen Y, Shelat AA, et al: Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285:10786-10796, 2010
18. Cheok CF, Verma CS, Baselga J, et al: Translating p53 into the clinic. Nat Rev Clin Oncol 8:25-37, 2011
19. Boeckler FM, Joerger AC, Jaggi G, et al: Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A 105:10360-10365, 2008
20. Joerger AC, Ang HC, Fersht AR: Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A 103:15056-15061, 2006 (Pubitemid 44583163)
21. Yu X, Vazquez A, Levine AJ, et al: Allele-specific p53 mutant reactivation. Cancer Cell 21:614-625, 2012
22. Foster BA, Coffey HA, Morin MJ, et al: Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510, 1999
23. Demma M, Maxwell E, Ramos R, et al: SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem 285:10198-10212, 2010
24. Bykov VJ, Issaeva N, Zache N, et al: Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280:30384-30391, 2005 (Pubitemid 41216221)
25. Zache N, Lambert JM, Rökaeus N, et al: Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2:70-80, 2008
26. Rippin TM, Bykov VJ, Freund SM, et al: Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119-2129, 2002 (Pubitemid 34311366)
27. Bykov VJ, Issaeva N, Shilov A, et al: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288, 2002 (Pubitemid 34250107)
28. Lambert JM, Gorzov P, Veprintsev DB, et al: PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:376-388, 2009
29. Bykov VJ, Zache N, Stridh H, et al: PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24:3484-3491, 2005 (Pubitemid 40756249)